drug-repurposer

Drug repurposing identifies new indications for existing drugs by analyzing target-based, compound-based, and disease-driven approaches. It evaluates potential uses through an 8-dimensional scoring system covering clinical evidence, mechanistic rationale, and regulatory feasibility.

Comprehensive drug indication analysis requires access to Open Targets, ChEMBL, openFDA FAERS, PubMed, and ClinicalTrials.gov. These dependencies provide the necessary target data, compound activities, adverse event reports, literature evidence, and clinical trial records.

A disease-driven approach searches for approved drugs suitable for unmet medical needs by analyzing disease targets. It evaluates existing compounds against disease profiles to pinpoint potential new indications using the 8-dimensional evaluation framework.

Yes, the 8-dimensional evaluation assesses commercial opportunity, safety compatibility, IP/exclusivity, clinical evidence, and regulatory feasibility. This scoring system provides a comprehensive profile for evaluating repurposing potential.

The compound-based approach finds related diseases for existing drugs based on their target activities. It leverages pharmacological data from ChEMBL and Open Targets to map drug interactions to new disease indications.

Yes, the target-based approach identifies drugs targeting specific disease-related targets. It integrates pharmaceutical analysis from Open Targets and PubMed to score and validate potential drug repurposing opportunities.